Further re Grant of Options

Stem Cell Sciences plc
20 December 2007



Press Release

For Immediate Release                                         20 December 2007

                             Stem Cell Sciences plc

                       Clarification for Grant of Options

Stem Cell Sciences plc announces clarification for options granted to Directors
on 18th December 2007:

Dr Alastair J. Riddell, the newly appointed Chief Executive Officer of Stem Cell
Sciences, as part of his remuneration package on joining the company, was
granted options to acquire 162,500 new Ordinary Shares in the Company at a
strike price of 29 pence per share.

These options vest over a four year period and the strike price is based upon
the average price of the three previous days trading to the grant date of 18th
December 2007.

Dr Peter Mountford, the founder of the company and retiring CEO who is now in
the position of Chief Technology Officer, was on stepping down from his role as
CEO and in recognition of his 13 years of service granted options to acquire
100,000 new Ordinary Shares in the Company at an exercise price of 50 pence per
share not 29 pence per share as previously announced.


                                    - Ends -

For further information, please contact:

Stem Cell Sciences plc (United Kingdom)
Sue Furber, Director of Finance and Company Secretary [phone]

Notes to Editors
Stem Cell Sciences plc (SCS, AIM: STEM, ASX: STC) is a global biotechnology
company providing the biological infrastructure of cells and cell culture media
to the burgeoning stem cell research market.

Academic and commercial use of stem cells in basic research and drug discovery
provides the Company with immediate and growing revenue streams and offsets the
cost of technology development for full scale cell production of SCS cell-based
therapeutics. These revenues are delivered via an integrated network of business
teams and regional offices in Edinburgh and Cambridge (UK), Melbourne (Australia
) and San Francisco (USA). This global reach provides the Company with the
direct access to markets through experienced personnel and local business
networks needed to drive SCS business growth in each region.

The key challenge for the successful application of stem cells in both research
and clinical applications is the reproducible supply of pure, fully
characterized stem cells and stem cell-derived specialised cells such as nerves
and muscle. This represents a significant technological challenge that will
require access to multiple technologies and a globally integrated stem cell
initiative.

To access cutting edge technologies on a rapid and on-going basis, Stem Cell
Sciences has built an exceptional network of highly interactive collaborations
with academic centres of excellence in the stem cell field. These collaborations
have been the source of our founding technologies and continue to provide an
expanding pipeline of products and intellectual property that are central to the
Company's strategy and success.

To facilitate research and technology transfer with its major collaborating
academic institutions, Stem Cell Sciences' business and scientific teams are
co-located on site or adjacent to the centres of excellence in independent
company facilities. The Company's key collaborating institutes include the
Wellcome Trust Centre for Stem Cell Research (University of Cambridge), the
Institute of Stem Cell Research (University of Edinburgh), RIKEN Centre for
Developmental Biology (Kobe) and the Australian Stem Cell Centre (Melbourne).

For further information on the company please visit: www.stemcellsciences.com



                      This information is provided by RNS
            The company news service from the London Stock Exchange